Governments across the globe are planning to take effective efforts and develop strategies in order minimize the burgeoning healthcare costs. Healthcare service providers are increasingly entering into collaborations with consumers, which in turn is likely to demonstrate financial and clinical benefit of services. Apart from this, there is increasing penetration of AI (artificial intelligence) technologies along with big-data analytics in the health technologies, in order to make decisions based on real-time.
A recent study by Future Market Insights predicts an outstanding 25.6% CAGR growth of market for connected drug delivery device during the anticipated period, 2015-2027. In addition, the market for connected drug delivery device is likely to touch an evaluation of nearly US$ 1,304.7Mn by 2027-end. Developing effective connected drug delivery device for end-users is possible to be a vital trend, increasingly impacting growth of market for connected drug delivery device. Besides, the report poses constructive insights for the growth of market for connected drug delivery device in the forthcoming years.
Analysts that have been part of this report development made sure that they have delivered valuable information as to how market for connected drug delivery device will expand through 2027. Additionally, our analysts have catered to the growing concerns of industry participants and market observers.
Are there any opportunities that you think can contribute towards growth of market for connected drug delivery device?
Yes. There is increase in the healthcare expenditure that is significantly creating opportunities for companies as well as hospitals for generating higher revenues. Development of innovative techniques for the purpose of handling and managing chronic diseases is likely to create opportunities for market growth in the forthcoming years.
What is trending in the market for connected drug delivery device?
Typical frequency with regards to self-injectable biologic stretching from a week, month or quarter, devices that deliver and contain drugs are likely to be highly intuitive. This trend is expected to continue in the forthcoming years due to providers and payers seeking increasing access to cloud-based and real-time data that helps in accurately assessing the adherence of patients with chronic diseases.
What are the major factors according to you that is contributing towards growth of market for connected drug delivery device?
Well, based on analysis, increasing efforts for shifting therapeutic processes from healthcare facilities to patient-convenient locations is likely to significantly contribute towards growth of market for connected drug delivery device in the forthcoming years. Growing efforts by leading manufacturers in collaborating with software companies in order to assess cloud-data system is also contributing towards the growth of global market.
What are the manufacturers currently working on for the expansion of market for connected drug delivery device?
Well, according to the analysis, manufacturers in the inhalers industry, especially the ones into helping patients suffering from chronic lung disease and asthma are taking immense efforts in developing new generation smart devices along with integration of sensors. This in turn will help in analyzing if and when patients are utilizing their prescribed puffs.
Can you provide some constructive insights with regards to regions in the market for connected drug delivery device?
Definitely yes. According to the analysis, North America is expected to be leading in the market for connected drug delivery device. Increasing geriatric populace of the U.S. is expected to increase the need for connected drug delivery device in the region. Apart from this, Western Europe is likely to trail North America in the forthcoming years.
Would you like to mention some key players in the market for connected drug delivery device?
Certainly yes. Some of the key players that analysts have profiled is inclusive of Biocorp Production SA, Cohero Health, 3M Company, Bayer AG, CeQur SA, Sagentia (Science Group) and West Pharmaceutical Services, Inc.
A sample of this report is available upon request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2755